ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Amgen, AstraZeneca and Novartis side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Amgen×AstraZeneca×Novartis×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AmgenAstraZenecaNovartis
studies on the registry1,0884,1973,900
open to participants now50298211
phase 3 studies under way5020094
reach primary completion within a year35168125
programswith a study of their own in two years24119+5 named only77+7 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAmgenAstraZenecaNovartis
Phase 1

Amgen: 8 of its 24 programs at phase 1

  1. AMG 691phase 1
  2. AMG 127phase 1
  3. etakafusp alfaphase 1
  4. Pan-KRAS Inhibitor AMG 410phase 1
  5. tambotatug pelitecanphase 1

and 3 more — sign in to see them all

33%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%
Phase 2

Amgen: 1 of its 24 programs at phase 2

  1. AMG 732phase 2
4%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. arumakimigphase 2
  4. QCZ484phase 2
  5. DDY391phase 2

and 30 more — sign in to see them all

45%
Phase 3

Amgen: 7 of its 24 programs at phase 3

  1. maridebart cafraglutidephase 3
  2. tarlatamabphase 3
  3. xaluritamigphase 3
  4. sotorasibphase 3
  5. olpasiranphase 3

and 2 more — sign in to see them all

29%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%
Approved, new studies

Amgen: 8 of its 24 programs at approved, new studies

  1. inebilizumabapproved, new study
  2. blinatumomabapproved, new study
  3. apremilastapproved, new study
  4. evolocumabapproved, new study
  5. romiplostimapproved, new study

and 3 more — sign in to see them all

33%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Amgen12 readouts · 3 phase 3·

Amgen, Dec ’26: 1 program whose next study reaches primary completion

  1. sotorasibphase 3 · Dec 17 · NCT04185883

Amgen, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. AMG 732phase 2 · Jan 6 · NCT06401044
  2. apremilastapproved, new study · Jan 10 · NCT07908641
  3. romosozumabapproved, new study · Jan 14 · NCT07811999
  4. maridebart cafraglutidephase 3 · Jan 21 · NCT06858839

Amgen, Feb ’27: 1 program whose next study reaches primary completion

  1. xaluritamigphase 3 · Feb 17 · NCT06613100

Amgen, Mar ’27: 1 program whose next study reaches primary completion

  1. AMG 691phase 1 · Mar 17 · NCT07745907

Amgen, Apr ’27: 2 programs whose next study reaches primary completion

  1. inebilizumabapproved, new study · Apr 13 · NCT05549258
  2. tarlatamabphase 3 · Apr 24 · NCT06598306

Amgen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. evolocumabapproved, new study · May 29 · NCT05284747
·

Amgen, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. afliberceptphase 3 · Jul 31 · NCT07614776
··

Amgen, Oct ’27: 1 program whose next study reaches primary completion

  1. AMG 127phase 1 · Oct 2 · NCT07590193
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. opnurasibphase 3 · Jan 25 · NCT04699188
  2. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 3 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · May 31 · NCT05397496
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Amgen

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 5

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 5

  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 62 in all. A program counts in each condition its studies name most.

ConditionAmgenAstraZenecaNovartis
Prostatic Neoplasmsall three · compare here

Amgen in Prostatic Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. xaluritamigphase 3

Their studies: Amgen’s studies of Prostatic Neoplasms in search

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Novartis in Prostatic Neoplasms: 13 programs

  1. Atrasentanphase 3
  2. actinium AC-225 vipivotide tetraxetanphase 3
  3. Gallium-68phase 3
  4. ARPIphase 3
  5. Lutetium-177phase 2

and 8 more — sign in to see them all

Their studies: Novartis’s studies of Prostatic Neoplasms in search

Carcinoma, Non-Small-Cell Lungall three · compare here

Amgen in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. sotorasibphase 3
  2. Pan-KRAS Inhibitor AMG 410phase 1
  3. tambotatug pelitecanphase 1
  4. romiplostimapproved, new study

Their studies: Amgen’s studies of Carcinoma, Non-Small-Cell Lung in search

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Novartis in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. opnurasibphase 3
  2. Lutetium-177phase 2
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1

Their studies: Novartis’s studies of Carcinoma, Non-Small-Cell Lung in search

Small Cell Lung Carcinomaall three · compare here

Amgen in Small Cell Lung Carcinoma: 4 programs

  1. tarlatamabphase 3
  2. etakafusp alfaphase 1
  3. tambotatug pelitecanphase 1
  4. Zocilurtatug Pelitecanphase 1

Their studies: Amgen’s studies of Small Cell Lung Carcinoma in search

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

Renal Insufficiencyall three · compare here

Amgen in Renal Insufficiency: 1 program

  1. olpasiranphase 3

Their studies: Amgen’s studies of Renal Insufficiency in search

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

Novartis in Renal Insufficiency: 2 programs

  1. PKN605phase 2
  2. asciminibapproved, new study

Their studies: Novartis’s studies of Renal Insufficiency in search

Renal Insufficiency, Chronicall three · compare here

Amgen in Renal Insufficiency, Chronic: 1 program

  1. Pegloticaseapproved, new study

Their studies: Amgen’s studies of Renal Insufficiency, Chronic in search

AstraZeneca in Renal Insufficiency, Chronic: 8 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. Berzanoflastphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency, Chronic in search

Novartis in Renal Insufficiency, Chronic: 2 programs

  1. Atrasentanphase 3
  2. OJR520phase 1

Their studies: Novartis’s studies of Renal Insufficiency, Chronic in search

Neoplasmsall three · compare here

Amgen in Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. teprotumumabapproved, new study

Their studies: Amgen’s studies of Neoplasms in search

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Novartis in Neoplasms: 2 programs

  1. tulmimetostatphase 2
  2. Alpelisibapproved, new study

Their studies: Novartis’s studies of Neoplasms in search

Arthritis, Rheumatoidall three · compare here

Amgen in Arthritis, Rheumatoid: 1 program

  1. dazodalibepphase 3

Their studies: Amgen’s studies of Arthritis, Rheumatoid in search

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

Novartis in Arthritis, Rheumatoid: 5 programs

  1. ianalumabphase 3
  2. rapcabtagene autoleucelphase 2
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  4. DKB903phase 1
  5. secukinumabapproved, new study

Their studies: Novartis’s studies of Arthritis, Rheumatoid in search

Atherosclerosisall three · compare here

Amgen in Atherosclerosis: 2 programs

  1. maridebart cafraglutidephase 3
  2. olpasiranphase 3

Their studies: Amgen’s studies of Atherosclerosis in search

AstraZeneca in Atherosclerosis: 3 programs

  1. laroprovstatphase 3
  2. baxdrostatphase 3
  3. Berzanoflastphase 2

Their studies: AstraZeneca’s studies of Atherosclerosis in search

Novartis in Atherosclerosis: 2 programs

  1. pelacarsenphase 3
  2. inclisiranapproved, new study

Their studies: Novartis’s studies of Atherosclerosis in search

Lupus Erythematosus, Systemicall three · compare here

Amgen in Lupus Erythematosus, Systemic: 1 program

  1. inebilizumabapproved, new study

Their studies: Amgen’s studies of Lupus Erythematosus, Systemic in search

Lymphoma, B-Cellall three · compare here

Amgen in Lymphoma, B-Cell: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Lymphoma, B-Cell in search

Cardiovascular Diseasesall three · compare here

Amgen in Cardiovascular Diseases: 1 program

  1. olpasiranphase 3

Their studies: Amgen’s studies of Cardiovascular Diseases in search

AstraZeneca in Cardiovascular Diseases: 2 programs

  1. laroprovstatphase 3
  2. balcinrenonephase 3

Their studies: AstraZeneca’s studies of Cardiovascular Diseases in search

Novartis in Cardiovascular Diseases: 2 programs

  1. pelacarsenphase 3
  2. DII235phase 2

Their studies: Novartis’s studies of Cardiovascular Diseases in search

Hypercholesterolemiaall three · compare here

Amgen in Hypercholesterolemia: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Hypercholesterolemia in search

AstraZeneca in Hypercholesterolemia: 2 programs

  1. laroprovstatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypercholesterolemia in search

Novartis in Hypercholesterolemia: 2 programs

  1. QCZ484phase 2
  2. inclisiranapproved, new study

Their studies: Novartis’s studies of Hypercholesterolemia in search

Purpura, Thrombocytopenic, Idiopathicall three · compare here

Amgen in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. romiplostimapproved, new study

Their studies: Amgen’s studies of Purpura, Thrombocytopenic, Idiopathic in search

AstraZeneca in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. pirtobrutinibphase 2

Their studies: AstraZeneca’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Novartis in Purpura, Thrombocytopenic, Idiopathic: 3 programs

  1. ianalumabphase 3
  2. Thrombopoietin Receptor Agonistphase 2
  3. eltrombopagapproved, new study

Their studies: Novartis’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Colorectal Neoplasmsall three · compare here

Amgen in Colorectal Neoplasms: 2 programs

  1. sotorasibphase 3
  2. afliberceptphase 3

Their studies: Amgen’s studies of Colorectal Neoplasms in search

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Novartis in Colorectal Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Colorectal Neoplasms in search

Pancreatic Neoplasmsall three · compare here

Amgen in Pancreatic Neoplasms: 1 program

  1. tambotatug pelitecanphase 1

Their studies: Amgen’s studies of Pancreatic Neoplasms in search

AstraZeneca in Pancreatic Neoplasms: 2 programs

  1. sonesitatug vedotinphase 3
  2. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Pancreatic Neoplasms in search

Novartis in Pancreatic Neoplasms: 1 program

  1. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Pancreatic Neoplasms in search

Coronary Artery Diseaseall three · compare here

Amgen in Coronary Artery Disease: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Coronary Artery Disease in search

AstraZeneca in Coronary Artery Disease: 1 program

  1. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Coronary Artery Disease in search

Novartis in Coronary Artery Disease: 1 program

  1. YMI024phase 2

Their studies: Novartis’s studies of Coronary Artery Disease in search

Lymphoma, Large B-Cell, Diffuseall three · compare here

Amgen in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Lymphoma, Large B-Cell, Diffuse in search

AstraZeneca in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Large B-Cell, Diffuse in search

Novartis in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. blinatumomabphase 2

Their studies: Novartis’s studies of Lymphoma, Large B-Cell, Diffuse in search

Precursor Cell Lymphoblastic Leukemia-Lymphomaall three · compare here

Amgen in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

AstraZeneca in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. Menin Inhibitor AZD3632phase 2

Their studies: AstraZeneca’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

Novartis in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. blinatumomabphase 2

Their studies: Novartis’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

Breast Neoplasms2 of 3 · compare here–

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Novartis in Breast Neoplasms: 6 programs

  1. Gallium-68phase 3
  2. Lutetium-177phase 2
  3. GVV858phase 2
  4. ERW316phase 2
  5. IEV407phase 1

and 1 more — sign in to see them all

Their studies: Novartis’s studies of Breast Neoplasms in search

Asthma2 of 3 · compare here

Amgen in Asthma: 1 program

  1. AMG 691phase 1

Their studies: Amgen’s studies of Asthma in search

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

–
Diabetes Mellitus, Type 22 of 3 · compare here

Amgen in Diabetes Mellitus, Type 2: 2 programs

  1. maridebart cafraglutidephase 3
  2. AMG 127phase 1

Their studies: Amgen’s studies of Diabetes Mellitus, Type 2 in search

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

–
Heart Failure2 of 3 · compare here–

AstraZeneca in Heart Failure: 6 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. balcinrenonephase 3
  4. Pexerelgonphase 2
  5. dapagliflozinapproved, new study

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Heart Failure in search

Novartis in Heart Failure: 1 program

  1. HJB647phase 1

Their studies: Novartis’s studies of Heart Failure in search

Lymphoma, Follicular2 of 3 · compare here–

AstraZeneca in Lymphoma, Follicular: 5 programs

  1. surovatamigphase 3
  2. camizestrantphase 3
  3. lenbelintidephase 3
  4. AZD9550phase 2
  5. AZD2389phase 2

Their studies: AstraZeneca’s studies of Lymphoma, Follicular in search

Novartis in Lymphoma, Follicular: 1 program

  1. pelabresibphase 3

Their studies: Novartis’s studies of Lymphoma, Follicular in search

Multiple Myeloma2 of 3 · compare here–

Novartis in Multiple Myeloma: 2 programs

  1. pelabresibphase 3
  2. zigakibartphase 3

Their studies: Novartis’s studies of Multiple Myeloma in search

Dermatitis, Atopic2 of 3 · compare here–

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

Novartis in Dermatitis, Atopic: 4 programs

  1. GIA632phase 2
  2. GHZ339phase 2
  3. DCY636phase 1
  4. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Dermatitis, Atopic in search

Obesity2 of 3 · compare here

Amgen in Obesity: 1 program

  1. maridebart cafraglutidephase 3

Their studies: Amgen’s studies of Obesity in search

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

–
Carcinoma, Renal Cell2 of 3 · compare here–

AstraZeneca in Carcinoma, Renal Cell: 3 programs

  1. volrustomigphase 3
  2. Actinium-225phase 3
  3. casdatifanphase 1

Their studies: AstraZeneca’s studies of Carcinoma, Renal Cell in search

Novartis in Carcinoma, Renal Cell: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Carcinoma, Renal Cell in search

Dyslipidemias2 of 3 · compare here

Amgen in Dyslipidemias: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Dyslipidemias in search

AstraZeneca in Dyslipidemias: 3 programs

  1. laroprovstatphase 3
  2. AZD4954phase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Dyslipidemias in search

–
Glomerulonephritis, IGA2 of 3 · compare here–

AstraZeneca in Glomerulonephritis, IGA: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Glomerulonephritis, IGA in search

Novartis in Glomerulonephritis, IGA: 3 programs

  1. iptacopanphase 3
  2. Atrasentanphase 3
  3. zigakibartphase 3

Their studies: Novartis’s studies of Glomerulonephritis, IGA in search

Hyperlipidemias2 of 3 · compare here

Amgen in Hyperlipidemias: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Hyperlipidemias in search

AstraZeneca in Hyperlipidemias: 3 programs

  1. laroprovstatphase 3
  2. Laroprovstat/ezetimibe FCDP-slow variantphase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hyperlipidemias in search

–
Hypertension2 of 3 · compare here–

AstraZeneca in Hypertension: 2 programs

  1. baxdrostatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypertension in search

Novartis in Hypertension: 2 programs

  1. QCZ484phase 2
  2. HJB647phase 1

Their studies: Novartis’s studies of Hypertension in search

Neoplasm Metastasis2 of 3 · compare here

Amgen in Neoplasm Metastasis: 1 program

  1. WRN Inhibitor AMG 436phase 1

Their studies: Amgen’s studies of Neoplasm Metastasis in search

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

–
Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here–

AstraZeneca in Squamous Cell Carcinoma of Head and Neck: 3 programs

  1. tremelimumabphase 3
  2. volrustomigphase 3
  3. monalizumabphase 3

Their studies: AstraZeneca’s studies of Squamous Cell Carcinoma of Head and Neck in search

Novartis in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Alpelisibapproved, new study

Their studies: Novartis’s studies of Squamous Cell Carcinoma of Head and Neck in search

Arthritis, Psoriatic2 of 3 · compare here

Amgen in Arthritis, Psoriatic: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of Arthritis, Psoriatic in search

–

Novartis in Arthritis, Psoriatic: 2 programs

  1. DDY391phase 2
  2. secukinumabapproved, new study

Their studies: Novartis’s studies of Arthritis, Psoriatic in search

Atypical Hemolytic Uremic Syndrome2 of 3 · compare here–

AstraZeneca in Atypical Hemolytic Uremic Syndrome: 2 programs

  1. ravulizumabapproved, new study
  2. eculizumabapproved, new study

Their studies: AstraZeneca’s studies of Atypical Hemolytic Uremic Syndrome in search

Novartis in Atypical Hemolytic Uremic Syndrome: 1 program

  1. iptacopanphase 3

Their studies: Novartis’s studies of Atypical Hemolytic Uremic Syndrome in search

Hemoglobinuria, Paroxysmal2 of 3 · compare here–

AstraZeneca in Hemoglobinuria, Paroxysmal: 2 programs

  1. ravulizumabapproved, new study
  2. eculizumabapproved, new study

Their studies: AstraZeneca’s studies of Hemoglobinuria, Paroxysmal in search

Novartis in Hemoglobinuria, Paroxysmal: 1 program

  1. iptacopanphase 3

Their studies: Novartis’s studies of Hemoglobinuria, Paroxysmal in search

Lupus Nephritis2 of 3 · compare here–

AstraZeneca in Lupus Nephritis: 1 program

  1. anifrolumabapproved, new study

Their studies: AstraZeneca’s studies of Lupus Nephritis in search

Novartis in Lupus Nephritis: 2 programs

  1. ianalumabphase 3
  2. rapcabtagene autoleucelphase 2

Their studies: Novartis’s studies of Lupus Nephritis in search

Lymphoma, Non-Hodgkin2 of 3 · compare here

Amgen in Lymphoma, Non-Hodgkin: 2 programs

  1. afliberceptphase 3
  2. blinatumomabapproved, new study

Their studies: Amgen’s studies of Lymphoma, Non-Hodgkin in search

–

Novartis in Lymphoma, Non-Hodgkin: 1 program

  1. blinatumomabphase 2

Their studies: Novartis’s studies of Lymphoma, Non-Hodgkin in search

Myasthenia Gravis2 of 3 · compare here

Amgen in Myasthenia Gravis: 1 program

  1. inebilizumabapproved, new study

Their studies: Amgen’s studies of Myasthenia Gravis in search

AstraZeneca in Myasthenia Gravis: 2 programs

  1. ravulizumabapproved, new study
  2. eculizumabapproved, new study

Their studies: AstraZeneca’s studies of Myasthenia Gravis in search

–
Neuromyelitis Optica2 of 3 · compare here

Amgen in Neuromyelitis Optica: 1 program

  1. inebilizumabapproved, new study

Their studies: Amgen’s studies of Neuromyelitis Optica in search

AstraZeneca in Neuromyelitis Optica: 2 programs

  1. ravulizumabapproved, new study
  2. eculizumabapproved, new study

Their studies: AstraZeneca’s studies of Neuromyelitis Optica in search

–
Ovarian Neoplasms2 of 3 · compare here–

AstraZeneca in Ovarian Neoplasms: 2 programs

  1. saruparibphase 3
  2. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Ovarian Neoplasms in search

Novartis in Ovarian Neoplasms: 1 program

  1. Alpelisibapproved, new study

Their studies: Novartis’s studies of Ovarian Neoplasms in search

Sjogren's Syndrome2 of 3 · compare here

Amgen in Sjogren's Syndrome: 1 program

  1. dazodalibepphase 3

Their studies: Amgen’s studies of Sjogren's Syndrome in search

–

Novartis in Sjogren's Syndrome: 2 programs

  1. ianalumabphase 3
  2. DDY391phase 2

Their studies: Novartis’s studies of Sjogren's Syndrome in search

Urinary Bladder Neoplasms2 of 3 · compare here–

AstraZeneca in Urinary Bladder Neoplasms: 2 programs

  1. datopotamab deruxtecanphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Urinary Bladder Neoplasms in search

Novartis in Urinary Bladder Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Urinary Bladder Neoplasms in search

Anemia, Aplastic2 of 3 · compare here

Amgen in Anemia, Aplastic: 1 program

  1. romiplostimapproved, new study

Their studies: Amgen’s studies of Anemia, Aplastic in search

–

Novartis in Anemia, Aplastic: 1 program

  1. eltrombopagapproved, new study

Their studies: Novartis’s studies of Anemia, Aplastic in search

Anemia, Sickle Cell2 of 3 · compare here–

AstraZeneca in Anemia, Sickle Cell: 1 program

  1. tarperprumigphase 2

Their studies: AstraZeneca’s studies of Anemia, Sickle Cell in search

Novartis in Anemia, Sickle Cell: 1 program

  1. ITU512phase 2

Their studies: Novartis’s studies of Anemia, Sickle Cell in search

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis2 of 3 · compare here–

AstraZeneca in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: 1 program

  1. tarperprumigphase 2

Their studies: AstraZeneca’s studies of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in search

Novartis in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: 1 program

  1. rapcabtagene autoleucelphase 2

Their studies: Novartis’s studies of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in search

Arthritis, Juvenile2 of 3 · compare here

Amgen in Arthritis, Juvenile: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of Arthritis, Juvenile in search

–

Novartis in Arthritis, Juvenile: 1 program

  1. arumakimigphase 2

Their studies: Novartis’s studies of Arthritis, Juvenile in search

COVID-192 of 3 · compare here

Amgen in COVID-19: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of COVID-19 in search

AstraZeneca in COVID-19: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of COVID-19 in search

–
Diabetic Nephropathies2 of 3 · compare here–

AstraZeneca in Diabetic Nephropathies: 1 program

  1. tozorakimabphase 3

Their studies: AstraZeneca’s studies of Diabetic Nephropathies in search

Novartis in Diabetic Nephropathies: 1 program

  1. Atrasentanphase 3

Their studies: Novartis’s studies of Diabetic Nephropathies in search

Glioblastoma2 of 3 · compare here–

AstraZeneca in Glioblastoma: 1 program

  1. AZD1390phase 1

Their studies: AstraZeneca’s studies of Glioblastoma in search

Novartis in Glioblastoma: 1 program

  1. Lutetium-177phase 2

Their studies: Novartis’s studies of Glioblastoma in search

Hematologic Neoplasms2 of 3 · compare here–

AstraZeneca in Hematologic Neoplasms: 1 program

  1. capivasertibphase 3

Their studies: AstraZeneca’s studies of Hematologic Neoplasms in search

Novartis in Hematologic Neoplasms: 1 program

  1. pelabresibphase 3

Their studies: Novartis’s studies of Hematologic Neoplasms in search

Homozygous Familial Hypercholesterolemia2 of 3 · compare here

Amgen in Homozygous Familial Hypercholesterolemia: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Homozygous Familial Hypercholesterolemia in search

–

Novartis in Homozygous Familial Hypercholesterolemia: 1 program

  1. inclisiranapproved, new study

Their studies: Novartis’s studies of Homozygous Familial Hypercholesterolemia in search

Idiopathic Pulmonary Fibrosis2 of 3 · compare here–

AstraZeneca in Idiopathic Pulmonary Fibrosis: 1 program

  1. AZD8965phase 2

Their studies: AstraZeneca’s studies of Idiopathic Pulmonary Fibrosis in search

Novartis in Idiopathic Pulmonary Fibrosis: 1 program

  1. LTP001phase 2

Their studies: Novartis’s studies of Idiopathic Pulmonary Fibrosis in search

Kidney Diseases2 of 3 · compare here–

AstraZeneca in Kidney Diseases: 1 program

  1. zibotentanphase 3

Their studies: AstraZeneca’s studies of Kidney Diseases in search

Novartis in Kidney Diseases: 1 program

  1. Atrasentanphase 3

Their studies: Novartis’s studies of Kidney Diseases in search

Liver Diseases2 of 3 · compare here

Amgen in Liver Diseases: 1 program

  1. maridebart cafraglutidephase 3

Their studies: Amgen’s studies of Liver Diseases in search

AstraZeneca in Liver Diseases: 1 program

  1. AZD2389phase 2

Their studies: AstraZeneca’s studies of Liver Diseases in search

–
Lung Neoplasms2 of 3 · compare here–

AstraZeneca in Lung Neoplasms: 1 program

  1. osimertinibapproved, new study

Their studies: AstraZeneca’s studies of Lung Neoplasms in search

Novartis in Lung Neoplasms: 1 program

  1. opnurasibphase 3

Their studies: Novartis’s studies of Lung Neoplasms in search

Lymphoma2 of 3 · compare here–

AstraZeneca in Lymphoma: 1 program

  1. PRMT5 Inhibitor AZD3470phase 2

Their studies: AstraZeneca’s studies of Lymphoma in search

Novartis in Lymphoma: 1 program

  1. pelabresibphase 3

Their studies: Novartis’s studies of Lymphoma in search

Macular Degeneration2 of 3 · compare here

Amgen in Macular Degeneration: 1 program

  1. afliberceptphase 3

Their studies: Amgen’s studies of Macular Degeneration in search

–

Novartis in Macular Degeneration: 1 program

  1. iptacopanphase 3

Their studies: Novartis’s studies of Macular Degeneration in search

Neoplasm, Residual2 of 3 · compare here

Amgen in Neoplasm, Residual: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Neoplasm, Residual in search

–

Novartis in Neoplasm, Residual: 1 program

  1. blinatumomabphase 2

Their studies: Novartis’s studies of Neoplasm, Residual in search

Polycystic Kidney, Autosomal Dominant2 of 3 · compare here–

AstraZeneca in Polycystic Kidney, Autosomal Dominant: 1 program

  1. AZD1613phase 1

Their studies: AstraZeneca’s studies of Polycystic Kidney, Autosomal Dominant in search

Novartis in Polycystic Kidney, Autosomal Dominant: 1 program

  1. farabursenphase 1

Their studies: Novartis’s studies of Polycystic Kidney, Autosomal Dominant in search

Psoriasis2 of 3 · compare here

Amgen in Psoriasis: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of Psoriasis in search

–

Novartis in Psoriasis: 1 program

  1. secukinumabapproved, new study

Their studies: Novartis’s studies of Psoriasis in search

Scleroderma, Diffuse2 of 3 · compare here

Amgen in Scleroderma, Diffuse: 1 program

  1. teprotumumabapproved, new study

Their studies: Amgen’s studies of Scleroderma, Diffuse in search

–

Novartis in Scleroderma, Diffuse: 1 program

  1. rapcabtagene autoleucelphase 2

Their studies: Novartis’s studies of Scleroderma, Diffuse in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Amgen 17 of 24 · AstraZeneca 68 of 119 · Novartis 56 of 77 programs (61 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5, Novartis: 7).